On Thursday, February 23 from 2:00 – 3:30 PM EST, Sanjin Zvonic, PhD, PCT’s Senior Director, Business Leader, Clinical Cell Therapy Manufacturing, will be speaking as part of a panel on a webinar hosted by AABB titled “Apheresis Optimization in Gene and Immunotherapy Development in Non-Mobilized Patients and Donors.”
PCT has earned re-accreditation by the Foundation for the Accreditation of Cellular Therapy (“FACT”). This accreditation confirms that PCT operates in compliance with the FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing and Administration at both its Allendale, New Jersey and Mountain View, California sites.
The following is an excerpt from a paper originally published online in the journal Cytotherapy on October 26, 2016, entitled, “Bioreactors for cell therapies: Current status and future advances.” The paper’s authors are Shannon Eaker, Eytan Abraham, Julie Allickson, Thomas A. Brieva, Dolores Baksh, Thomas R.J. Heathman, Biren Mistry, and Nan Zhang.
The following is an excerpt of an article I wrote that was originally published in the October 2016 issue of The Medicine Maker.
Some companies still fail to look beyond science and clinical need. In the most heartbreaking of cases, clinical success is followed by commercial bankruptcy. When a company is focused on clinical trials,
On October 5thand 6th, PCT will take part in the annual Cell & Gene Meeting on the Mesa, hosted by the Alliance for Regenerative Medicine (ARM) in La Jolla, California. According to ARM, this conference brings together senior executives and top decision-makers in the industry with the scientific community to advance cutting-edge research into cures.